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Abstract
The type I interferon (IFN) response is imperative for the establishment of the early antiviral
immune response. Here we report the identification of the first type I IFN antagonist encoded
by murine cytomegalovirus (MCMV) that shuts down signaling following pattern recognition
receptor (PRR) sensing. Screening of an MCMV open reading frame (ORF) library identified
M35 as a novel and strong negative modulator of IFNβ promoter induction following activa-
tion of both RNA and DNA cytoplasmic PRR. Additionally, M35 inhibits the proinflammatory
cytokine response downstream of Toll-like receptors (TLR). Using a series of luciferase-
based reporters with specific transcription factor binding sites, we determined that M35 tar-
gets NF-κB-, but not IRF-mediated, transcription. Expression of M35 upon retroviral trans-
duction of immortalized bone marrow-derived macrophages (iBMDM) led to reduced IFNβ
transcription and secretion upon activation of stimulator of IFN genes (STING)-dependent
signaling. On the other hand, M35 does not antagonize interferon-stimulated gene (ISG) 56
promoter induction or ISG transcription upon exogenous stimulation of the type I IFN recep-
tor (IFNAR). M35 is present in the viral particle and, upon MCMV infection of fibroblasts, is
immediately shuttled to the nucleus where it exerts its immunomodulatory effects. Deletion
of M35 from the MCMV genome and hence from the viral particle resulted in elevated type I
IFN transcription and secretion in vitro and in vivo. In the absence of M35, lower viral titers
are observed during acute infection of the host, and productive infection in the salivary
glands was not detected. In conclusion, the M35 protein is released by MCMV immediately
upon infection in order to deftly inhibit the antiviral type I IFN response by targeting NF-κB-
mediated transcription. The identification of this novel viral protein reinforces the importance
of timely countermeasures in the complex relationship between virus and host.
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Author summary
The herpesvirus cytomegalovirus can cause severe morbidity in immunosuppressed peo-
ple and poses a much greater global problem in the context of congenital infections than
the Zika virus. To establish infection, cytomegalovirus needs to modulate the antiviral
immune response of its host. One of the first lines of defense against viral infections is the
type I interferon response which is activated by cellular sensors called pattern recognition
receptors. These receptors sense viral entry and rapidly induce the transcription of type I
interferons, which are instrumental for the induction of an antiviral state in infected and
surrounding cells. We have identified the first viral protein encoded by murine cytomega-
lovirus, the M35 protein, that counteracts type I interferon transcription downstream of
multiple pattern recognition receptors. We found that this viral countermeasure occurs
shortly after viral entry into the host cell, as M35 is delivered with the viral particle. M35
then localizes to the nucleus where it modulates NF-κB-mediated transcription. In vivo,
murine cytomegalovirus deficient of the M35 protein replicates to lower levels in spleen
and liver and cannot establish a productive infection in the salivary glands, which is a key
site of viral transmission, highlighting the important role of M35 for the establishment of
infection. Our study provides novel insights into the complex interaction between cyto-
megalovirus and the innate immune response of its host.
Introduction
The ability of a virus to escape or counter host immune responses is crucial for the establish-
ment of a successful infection in the host. Exquisite manipulation and targeting of cellular
checkpoints have been hallmarks of the specific adaptation of herpesviruses to their hosts. The
betaherpesvirus cytomegalovirus (CMV) encodes within its large 230 kilobases genome
numerous proteins involved in the evasion of cellular innate and adaptive immune responses
[1–3]. Additionally, CMV has been shown to antagonize the production of signaling molecules
such as type I interferons (IFN) and proinflammatory cytokines, which are amongst the first
messengers of an incoming viral attack [4].
While herpesviral infection can be asymptomatic in healthy individuals, deficiencies in
innate immunity lead to severe morbidity upon infection [5]. The innate immune system is
activated within hours of infection and is crucial for the initiation of the adaptive immune
response. The type I IFN response is one of the first following CMV infection [6] and plays a
critically protective role against murine CMV (MCMV) infection [7,8]. Additionally, human
CMV (HCMV) infection can be controlled by either enhancing or inhibiting the type I IFN
response in cell culture models [9–11].
Initiation of the innate immune response depends on the recognition of pathogen-associ-
ated molecular patterns (PAMP) by pattern recognition receptors (PRR). Toll-like receptors
(TLR) are type I transmembrane proteins, located either at the cell surface or within endo-
somes, and recognize nucleic acids or structural components unique to foreign invaders
[12,13]. More recently, several cytoplasmic nucleic acid sensors have been described that rec-
ognize aberrantly localized RNA or DNA. RNA sensors include RIG-I-like receptors (RLR)
such as RIG-I or MDA5 [14,15]. The most recently described cytoplasmic DNA sensor (CDS)
is cyclic GMP-AMP synthase (cGAS), which produces the second messenger 2’3’-cGAMP
upon recognition of cytosolic DNA [16–19]. Following binding of their specific foreign ligand,
TLR, RLR, and CDS recruit or activate the corresponding adaptor proteins, MyD88/TRIF,
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MAVS, and STING, respectively. This leads to the nuclear translocation of the transcriptional
activators interferon regulatory factors (IRF) and nuclear factor κB (NF-κB), resulting in the
production of the type I interferons IFNα and IFNβ, as well as of proinflammatory cytokines
[20,21]. Transcription of the IFNβ gene is regulated by the concerted action of multiple tran-
scriptional regulators [22–24]. The enhancer region in the IFNβ promoter contains binding
regions, so called positive regulatory domains (PRD), for members of the AP-1 family
(PRD-IV), the IRF family (PRD-III and PRD-I) and the NF-κB family (PRD-II), which all con-
tribute to effective transcription. The subsequent binding of IFNα/β to the IFN receptor
(IFNAR) leads to the upregulation of various interferon-stimulated genes (ISG), resulting in
the creation of an antiviral state [25–28].
Myeloid cells are important innate immune effectors and play a crucial role in the induction
of the adaptive immune response. Myeloid dendritic cells (DC) and macrophages are permis-
sive to CMV infection [29–34] and are important vehicles for viral dissemination and serve as
latency reservoirs [29,35–37]. Plasmacytoid DC (pDC) and conventional DC (cDC) are the
major sources of type I IFN secretion upon encounter with MCMV [38], although the PRR sig-
naling pathways differ. The type I IFN response in pDC is exclusively TLR-dependent, whereas
RLR and CDS are important sensors in bone marrow-derived macrophages (BMDM) and
cDC.
Both cytokines and receptors on myeloid cells are targeted by CMV evasion mechanisms
[39,40]. Upon HCMV infection, the protein levels of the CDS interferon gamma inducible
protein 16 (IFI16), as well as of the transcription factors IRF3 and NF-κB are steadily downre-
gulated [41], indicating that viral proteins target these important determinants of CMV infec-
tion [4]. For example, HCMV pUL37x1 has been shown to antagonize signaling downstream
of the RLR adaptor MAVS in HeLa cells [42] and more recently, HCMV UL83 was observed
to interact with and impede oligomerization of IFI16 in the nucleus, leading to reduced IFN
signaling in fibroblasts [43]. Since HCMV infection cannot be studied in the natural host and
therefore the effects of HCMV immunomodulators cannot be fully understood, we chose
MCMV as a model in which to dissect the intricate pathways following PRR sensing and sub-
sequent initiation of the type I IFN response. Thus far, the only known type I IFN antagonist
in MCMV is M27, which targets STAT2 for proteasomal degradation, thereby inhibiting sig-
naling downstream of the IFNAR [6,39,44,45]. Notably, M45 is the only MCMV protein
known so far to interfere with signaling downstream of PRR sensing. This anti-apoptotic
protein first activates [46] and later inhibits the activation of NF-κB via interaction with the
regulatory protein NF-κB essential modulator (NEMO) [47], leading to regulation of the
proinflammatory cytokine response upon MCMV infection.
Here, we describe M35 as the first MCMV protein identified to indiscriminately antagonize
the induction of type I IFN downstream of multiple PRR. Upon MCMV infection, M35 shut-
tles immediately to the nucleus to exert its immune modulatory effect by negatively regulating
NF-κB-mediated transcription of type I IFN. We show that infection with an MCMV recombi-
nant lacking M35 leads to the loss of regulation of the type I IFN response, resulting in elevated
type I IFN responses and profound viral attenuation in the host.
Results
The MCMV M35 protein negatively modulates signaling of pattern
recognition receptors
Multiple MCMV immunoevasins of natural killer cell- and T cell-mediated immunity have
been identified and well characterized. Comparatively, however, the mechanisms by which
MCMV shuts down innate immune signaling are poorly understood. We sought viral proteins
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regulating the induction of type I IFN transcription, which is the very first response upon sens-
ing of viral nucleic acids by PRR. We rationalized that modulators of type I IFN induction
encoded by MCMV would be tegument proteins, which are introduced into infected cells with
the virions, or proteins expressed with immediate-early (IE) kinetics, consistent with the need
to modulate the immune response immediately upon infection. To test this, we used an IFNβ-
based luciferase reporter assay to screen for modulators of type I IFN transcription in MCMV.
Briefly, we co-transfected NIH3T3 fibroblasts with expression constructs of untagged known
or predicted tegument or IE MCMV proteins [48–50] derived from an MCMV ORF library
[51] with a reporter plasmid composed of the endogenous murine IFNβ promoter upstream of
the firefly luciferase gene (IFNβ-luc) as well as a Renilla luciferase construct (pRL-TK) as a
transfection control. 24 hours post transfection cells were infected with Newcastle disease
virus (NDV), which is sensed by RIG-I and leads to strong induction of type I IFN transcrip-
tion [52].
As expected, infection with NDV in the presence of empty vector alone led to high IFNβ
promoter induction. As a positive control, we included influenza NS1, a well-characterized
antagonist of RIG-I signaling [53–56], which clearly reduced induction of the IFNβ promoter
(Fig 1A). The majority of MCMV tegument and IE proteins did not affect or only mildly
affected induction of the IFNβ promoter after NDV infection and in these cases, luciferase
activity was comparable to that of empty vector transfected cells (Fig 1A). However, the M45
protein, known to target NF-κB-dependent signaling [46,47], and the M35 protein strongly
inhibited induction of the IFNβ promoter upon NDV infection (Fig 1A). We decided to focus
on the largely uncharacterized M35 protein, since it should be present immediately after infec-
tion as a component of the viral particle [48]. The addition of a C-terminal V5-tag to M35
retained its modulatory effect on the IFNβ promoter reporter, compared to the corresponding
empty vector (Fig 1B). Additionally, upon stimulation with poly(I:C) following transfection,
which is sensed by the RLR RIG-I/MDA5 [57,58], we likewise observed that M35 negatively
regulates IFNβ promoter induction (Fig 1C).
The cGAS-STING pathway is essential for mounting a type I IFN response against various
DNA viruses [59–62]. MCMV induces STING-dependent responses [63,64] and we have
observed that STING is essential for type I IFN secretion upon MCMV infection of BMDM
(S1 Fig). We therefore assessed the effect of M35 on cGAS-STING-dependent type I IFN
induction by an IFNβ-based luciferase reporter assay. We made use of 293T cells, which do
not express endogenous cGAS or STING, and overexpressed cGAS and STING to reconstitute
and activate this pathway. The cells were further co-transfected with IFNβ-luc, the Renilla con-
struct pRL-TK, and pcDNA, ORF36-myc or M35-V5. As expected, our positive control
ORF36, encoded by Kaposi’s sarcoma-associated herpesvirus (KSHV) and known to inhibit
IRF3 activity [65], downmodulated induction of IFNβ transcription downstream of cGAS-ST-
ING signaling. In this assay, MCMV M35 suppressed cGAS-STING dependent IFNβ tran-
scription comparably to KSHV ORF36 (Fig 1D).
Next, we examined the effect of M35 on IFNβ transcription in BMDM. Upon stimula-
tion of immortalized BMDM (iBMDM) stably expressing myc-tagged β-galactosidase
(LacZ) or M35 with the cGAS product cGAMP, we observed strong induction of IFNβ tran-
scription in the presence of the LacZ control (Fig 1E). In contrast, in the presence of M35,
IFNβ transcription was strongly inhibited. This reduction in transcription correlates with a
decrease in the levels of secreted IFNβ upon cGAMP stimulation in the presence of M35
(Fig 1F).
As MyD88-dependent signaling has been shown to be crucial for control of MCMV infec-
tion [66–68], we sought to examine if the immunomodulatory role of M35 extends to TLR sig-
naling. Upon stimulation of iBMDM stably expressing M35-myc with the TLR4 agonist LPS
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Fig 1. The MCMV M35 protein inhibits signaling of multiple pattern recognition receptors. (A) NIH3T3 fibroblasts
were co-transfected with a reporter plasmid containing firefly luciferase under the control of the murine IFNβ promoter
(IFNβ-Luc) together with a Renilla luciferase normalization control (pRL-TK) and influenza NS1 or MCMV ORFs known or
predicted to code for tegument or immediate-early proteins or their corresponding empty vector (pcDNA and pDEST40,
respectively). At 24 hours post transfection, cells were treated with medium or stimulated by infection with Newcastle
MCMV M35 is a novel antagonist of pattern recognition receptor signaling
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or the TLR9 agonist CpG-B 1826, we observed lower levels of secreted TNFα compared to the
empty vector control (Fig 1G). These data show that the M35 protein alone is a negative mod-
ulator of the induction of innate immune signaling downstream of multiple PRR.
M35 does not target IFNAR-dependent signaling
To determine whether the reduced induction of IFNβ transcription observed in the presence
of M35 is caused by inhibition of IFNAR signaling, which induces a positive feedback loop to
further enhance IFNβ transcription, a reporter assay was utilized to assess induction of IFNAR
signaling upon stimulation with recombinant IFNβ. As a positive control, we included
MCMV M27, which is known to target IFNAR-dependent signaling by degrading STAT2
[44]. 293T cells were co-transfected with expression constructs of V5-tagged LacZ, M27 or
M35 along with an ISG56 promoter firefly luciferase reporter plasmid and the Renilla
(pRL-TK) construct. IFNAR signaling leading to ISG56 promoter induction was activated by
the addition of recombinant IFNβ to the cell culture medium. Simultaneously, we performed
the cGAS-STING-IFNβ luciferase based assay described in Fig 1D to verify M35 expression.
As expected, M27 strongly inhibited ISG56 promoter induction upon IFNβ stimulation (Fig
2A, left panel). Interestingly, M27 also modulated IFNβ promoter activity upon activation of
cGAS-STING signaling (Fig 2A, right panel). However, since 293T cells express the IFNAR
[69], this result very likely reflects M27 modulation downstream of IFNAR signaling, which
induces IRF7 transcription needed to further enhance IFNβ transcription. In contrast, while
M35 strongly inhibited IFNβ promoter induction downstream of cGAS-STING signaling as
observed earlier, it had no effect on the induction of ISG56 promoter activity upon IFNβ stim-
ulation (Fig 2A).
In addition, we analyzed iBMDM stably expressing myc-tagged LacZ or M35 for ISG
induction upon stimulation with recombinant IFNβ. While M35 inhibited IFNβ transcription
upon stimulation with cGAMP (Fig 1E), we did not observe an effect on the transcription of
the ISG CXCL10 and IFIT3 following stimulation with recombinant IFNβ (Fig 2B).
Taken together, these data show that M35 selectively targets transcription of IFNβ down-
stream of PRR, but not IFNAR-induced signal transduction upon stimulation with exogenous
IFNβ.
disease virus (NDV). 21 hours p.i. cells were lysed for analysis of luciferase activity. Luciferase fold induction was
calculated based on firefly luciferase values normalized to Renilla luciferase from stimulated samples divided by
corresponding values from unstimulated samples. Data set is combined from one to four independent experiments and
represented as mean ± SD. (B) NIH3T3 fibroblasts were co-transfected with the IFNβ-Luc and pRL-TK luciferase plasmids
described in (A) as well as V5-tagged M35 or pcDNA and luciferase assay was performed following stimulation as for (A).
Data is combined from three independent experiments and shown as mean ± SD. (C) NIH3T3 fibroblasts were co-
transfected as described in (B) and cells stimulated with 10 μg/ml of poly(I:C) in the presence of Lipofectamine 2000 or
Lipofectamine 2000 alone for 6 hours before lysis for analysis by luciferase assay. Data is combined from three
independent experiments and shown as mean ± SD. (D) 293T cells were co-transfected with expression plasmids for either
cGAS (stimulated) or GFP (unstimulated) together with mCherry-STING, the IFNβ-Luc and pRL-TK luciferase plasmids,
and either pcDNA, myc-tagged KSHV ORF36 or V5-tagged M35. At 20 hours post transfection, cells were lysed and
luciferase production was analyzed. Data is combined from four independent experiments and shown as mean ± SD. (E)
Immortalized BMDM stably expressing myc-tagged LacZ or M35 were stimulated by addition of 3 μg/ml cGAMP or left
unstimulated. RNA was extracted at indicated time points and IFNβ induction was measured by quantitative RT-PCR and
expressed as IFNβ induction normalized to the housekeeping gene Rpl8. Data is shown as mean ± SD and combined from
two independent experiments. (F) Immortalized BMDM stably expressing myc-tagged LacZ or M35 were stimulated by
addition of indicated amounts of cGAMP and supernatant was collected 16 hours later and analyzed by IFNβ ELISA. Data
is shown as mean ± SD and representative of two independent experiments. (G) Immortalized BMDM stably expressing
myc-tagged M35 or the corresponding empty vector (pMSCV) were stimulated by addition of 10 ng/ml LPS or 1 μM CpG-B
1826 and supernatant collected at 16 hours post stimulation for analysis by TNFα ELISA. Data is combined from three
independent experiments and shown as mean ± SD.***p<0.001, ****p<0.0001.
https://doi.org/10.1371/journal.ppat.1006382.g001
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M35 does not affect the activation or translocation of key transcription
factors
We have thus far shown that M35 alone is a potent inhibitor of type I IFN and proinflamma-
tory cytokine induction downstream of multiple PRR. Next, we sought to pinpoint the stage of
Fig 2. M35 does not target signaling downstream of the type I IFN receptor. (A) 293T cells were co-
transfected with a reporter plasmid containing the endogenous ISG56 promoter cloned upstream of the firefly
luciferase gene, pRL-TK and V5-tagged versions of LacZ, M27 or M35. 24 hours post transfection, cells were
stimulated by addition of 0.1 ng/ml recombinant human IFNβ or left unstimulated. At 16 hours post stimulation,
cells were lysed for analysis of luciferase production (left panel). Simultaneously, 293T cells were co-
transfected with expression constructs for cGAS (stimulated) or GFP (unstimulated) together with mCherry-
STING, the IFNβ-Luc and pRL-TK luciferase plasmids, and V5-tagged versions of LacZ, M27 or M35. Cells
were lysed at 20 hours post transfection for analysis of luciferase production (right panel). Luciferase fold
induction was calculated based on luciferase values normalized to Renilla from stimulated samples divided by
corresponding values from unstimulated samples. For both panels, data is combined from four independent
experiments and shown as mean ± SD. (B) Immortalized BMDM stably expressing myc-tagged LacZ or M35
were stimulated by addition of 100 U/ml of recombinant murine IFNβ or left unstimulated. Cells were lysed for
RNA extraction at indicated timepoints for analysis of ISG transcription by quantitative RT-PCR (left panel:
CXCL10, right panel: IFIT3) and normalized to the housekeeping gene Rpl8. Data is shown as mean ± SD
and combined from three independent experiments.
https://doi.org/10.1371/journal.ppat.1006382.g002
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the innate signaling cascade which M35 targets. In NIH3T3 cells stably expressing M35-myc,
we observed that M35 was not detected in the cytoplasm (Fig 3A), but rather diffusely localized
in the nucleus and clearly excluded from the nucleoli (Fig 3B). This suggests that M35 likely
exerts its immunomodulatory effect from the nucleus. Based on this hypothesis, phosphoryla-
tion of IRF3 and p65, which occurs in the cytoplasm upon PRR activation, as well as subse-
quent IRF3 and p65 nuclear translocation, should be unaffected in the presence of M35.
Accordingly, we did not observe any differences in IRF3 phosphorylation (Fig 4A and S2A
Fig) nor nuclear translocation upon RLR activation in the absence or presence of M35 (Fig
4B). Similarly, M35 did not affect the phosphorylation of p65 (Fig 4C and S2B Fig) nor the
kinetics of p65 translocation upon RLR activation (Fig 4D).
M35 shuts down transcription induced by the NF-κB transcription factor,
but not by IRF
Our data has shown that M35 negatively regulates IFNβ transcription (Fig 1). Since tran-
scription of the IFNβ gene is regulated by the concerted action of multiple transcriptional
regulators and since M35 is localized to the nucleus, we sought to determine whether M35
acts by exclusively targeting IRF- or NF-κB-mediated transcription of the IFNβ gene or
both. To address this, we made use of previously reported luciferase reporter plasmids: the
p125 reporter consists of the human IFNβ promoter region (-125 to +19), which includes
the IFNβ enhancer consisting of the PRD-IV, -III, -I and -II region (Fig 5). While IRF were
shown to bind to the PRD-III and -I regions, the NF-κB transcription factor binds to the
PRD-II region (Fig 5). The p125AA reporter carries two mutations (CC to AA, Fig 5) within
the NF-κB binding site of the PRD-II region, which were reported to abrogate binding of
NF-κB [70]. In addition, we used an NF-κB reporter containing 5 repeats of the NF-κB con-
sensus sequence (pNF-κB). To analyze for IRF-mediated transcriptional activation, we used
the p55-CIB reporter [71], which contains 8 tandem repeat motifs (AAGTGA, highlighted
in bold in the PRD-I region), corresponding to seven repeats of an IRF binding element (Fig
5). We tested responsiveness of these reporters as well as of our previously described murine
IFNβ reporter by activating IFNβ transcription with a constitutively active IRF3 mutant
(IRF3-5D). As expected, expression of IRF3-5D resulted in activation of the IFNβ, p55-CIB,
Fig 3. M35 is localized to the nucleus, but excluded from nucleoli. NIH3T3 fibroblasts stably expressing LacZ-myc or M35-myc or empty vector
(pQCXIH) were fixed for immunolabeling with a mouse anti-myc antibody and either a rabbit anti-calnexin (A) or rabbit anti-fibrillarin (B) antibody
and imaged by confocal microscopy. Nuclei were stained with Hoechst. Scale bars represent 10 μm.
https://doi.org/10.1371/journal.ppat.1006382.g003
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Fig 4. M35 does not target the phosphorylation or nuclear translocation of key transcription factors. (A) Immortalized BMDM stably
expressing LacZ-myc or M35-myc were stimulated by addition of 3 μg/ml cGAMP and cells lysed at indicated time points. Lysates were
separated by SDS-PAGE and endogenous IRF3 and phospho-IRF3 were detected with specific antibodies. Expression of myc-tagged LacZ and
M35 was verified with a myc-specific antibody. Immunoblot shown is representative of three independent experiments. (B) NIH3T3 fibroblasts
stably expressing myc-tagged LacZ or M35 and eGFP-IRF3 were stimulated by transfection of 10 μg/ml poly(I:C) with Lipofectamine 2000. At
MCMV M35 is a novel antagonist of pattern recognition receptor signaling
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p125 and p125-AA reporters, but not of the pNF-κB reporter (S3 Fig). To analyze if M35
negatively affects transcription of these reporters, we overexpressed cGAS and STING in
293T cells to activate IFNβ transcription, and co-transfected the various reporter plasmids
(Fig 5). First, we confirmed that the immunomodulatory effect of M35 was preserved upon
indicated times post stimulation, cells were fixed for immunolabeling with a mouse anti-myc antibody and imaged by confocal microscopy (upper
panel). Nuclei were stained with Hoechst. Scale bars represent 10 μm. Corresponding counts for cells showing nuclear IRF3 (lower panel) are
represented as the percentage of total cells (with a minimum of 100 cells counted per timepoint). Data is shown as mean ± SD and combined
from two independent experiments. (C) NIH3T3 fibroblasts stably expressing myc-tagged M35 or corresponding empty vector pQCXIH were
stimulated by transfection of 10 μg/ml poly(I:C) in the presence of Lipofectamine 2000 and cells were lysed at indicated time points. Lysates were
separated by SDS-PAGE and endogenous p65, phospho-p65 and tubulin were detected with specific antibodies. Expression of myc-tagged M35
was verified with a myc-specific antibody. Immunoblot shown is representative of three independent experiments. (D) NIH3T3 fibroblasts stably
expressing myc-tagged M35 or corresponding empty vector pQCXIH were stimulated as for (B). At indicated times post stimulation, cells were
fixed for immunolabeling with a mouse anti-myc antibody and a rabbit anti-p65 antibody and imaged by confocal microscopy (upper panel).
Nuclei were stained with Hoechst. Scale bars represent 10 μm. Corresponding counts for cells showing nuclear p65 (lower panel) are
represented as percentage of total cells (with a minimum of 300 cells counted per timepoint). Data is shown as mean ± SD and combined from
two independent experiments.
https://doi.org/10.1371/journal.ppat.1006382.g004
Fig 5. M35 targets NF-κB- but not IRF-mediated transcription. (A) 293T cells were co-transfected with expression plasmids
for either cGAS (stimulated) or GFP (unstimulated) together with mCherry-STING, the p125 and pRL-TK luciferase plasmids,
and V5-tagged M35 or empty vector control (pcDNA). At 20 hours post transfection, cells were lysed for analysis of luciferase
production. Luciferase fold induction was calculated based on firefly luciferase values normalized to Renilla luciferase from
stimulated samples divided by corresponding values from unstimulated samples. The p125 reporter contains the IFNβ enhancer
consisting of PRD-IV, -III, -I and -II (sequence of the IFNβ enhancer is shown below). (B) As for (A) except with the luciferase
reporter pNF-κB instead of p125. (C) As for (A) except with the p125-AA luciferase plasmid instead of p125. p125-AA contains
two nucleotide exchanges within the NF-κB binding site in the PRD-II region (highlighted in red). (D) As for (A) but with the
p55-CIB luciferase plasmid instead of p125. p55-CIB contains 8 tandem repeat motifs (AAGTGA, highlighted in bold in the PRD-I
region), corresponding to 7 repeats of an IRF binding element. Data is combined from three (A-C) or four (D) independent
experiments and shown as mean ± SD. For all, n.s. indicates not significant, **p<0.01, ****p<0.0001.
https://doi.org/10.1371/journal.ppat.1006382.g005
MCMV M35 is a novel antagonist of pattern recognition receptor signaling
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006382 May 25, 2017 10 / 35
induction of the truncated human IFNβ promoter p125, which contains the intact IFN
enhancer (Fig 5A). Notably, M35 had a strong negative effect on transcription when NF-κB
binding sites alone were present (pNF-κB) (Fig 5B). However, when NF-κB binding to
PRD-II is disrupted by the CC to AA mutation in the PRD-II region, but IRF binding sites
within PRD-III and -I are left intact (p125AA), the negative regulatory effect of M35 is strik-
ingly less pronounced (Fig 5C). In agreement with this finding, modulation by M35 is lost if
only the IRF consensus binding site is present (p55-CIB) (Fig 5D). Collectively, these data
suggest that M35 negatively affects the IFNβ response downstream of PRR by targeting NF-
κB-mediated, but not IRF-mediated, transcription.
Upon MCMV infection, trafficking of tegument M35 to the nucleus
precedes translocation of p65
Next, we wanted to assess the role of M35 in evading host responses in the context of MCMV
infection. We used en passant mutagenesis to construct several MCMV recombinants target-
ing M35. First, we generated a recombinant MCMV designated MCMV-M35stop, in which a
16 basepair (bp) stop cassette was inserted after the first 222 nucleotides (nt) of the M35 ORF
(Fig 6A), leading to premature termination of translation of M35. In addition, we constructed
a revertant virus in which expression of full-length M35 protein was restored (MCMV-
M35stop-REV). Lastly, we generated a recombinant virus in which a myc/His tag was C-termi-
nally fused to M35 (MCMV-M35-myc) (Fig 6A). To confirm the presence or absence of M35
in our recombinants, we lysed purified MCMV virions and subjected them to immunoblotting
(Fig 6B). Using an M35-specific monoclonal antibody that was generated by us, we confirmed
the presence of full-length M35 in both WT and MCMV-M35stop-REV virions, and the
absence of M35 protein in MCMV-M35stop virions (Fig 6B). Additionally, we verified the
presence of myc-tagged M35 protein in MCMV-M35-myc virions as well as low amounts of
untagged M35 (Fig 6B). As a loading control, the amount of MCMV glycoprotein B (gB) was
also analyzed.
Consistent with our observations, M35 has previously been shown to be virion-associated
by mass spectrometry analysis [48]. However, de novo M35 protein expression in MCMV
infected cells has not been analyzed. Reports indicate that M35 mRNA may be expressed at
early or late time points in the MCMV replication cycle [50,72]. Expression and localization of
virion-delivered M35 protein in the context of infection has also not yet been shown. To char-
acterize the kinetics of M35 protein expression upon MCMV infection, we infected NIH3T3
fibroblasts with MCMV-M35-myc and analyzed M35-myc protein expression at different time
points post infection by immunoblotting. The myc-specific antibody did not detect any pro-
teins from WT MCMV infected cells demonstrating its specificity (Fig 6C). Representative
immediate-early (IE1), early (M45) and late (gB) proteins were expressed with the expected
kinetics. M35-myc was detected early after infection and remained stable until 6.5 hours post
infection (p.i.). Little to no M35-myc was detected at 12 and 18 hours p.i., but M35 protein
expression could be detected again 24 hours p.i. As expected for a viral tegument protein, we
detected high levels of M35 protein at 48 hours (Fig 6C). To assess if M35 protein detected up
to 6.5 hours p.i. was virion-delivered protein or de novo synthesized M35 protein, we per-
formed the same expression analysis in the presence of the transcriptional inhibitor actinomy-
cin D, which prevents any viral gene transcription. Indeed, we observed M35 protein at
comparable levels to untreated cells within the first 6.5 hours of infection, but notably did not
detect any M35 protein at 24 or 48 hours p.i. (Fig 6C). This indicates that M35 is delivered into
infected cells as part of the virion, remains stable for several hours p.i., and is only synthesized
de novo at late time points.
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Fig 6. Upon MCMV infection, delivery of tegument M35 to the nucleus precedes translocation of p65. (A) Schematic representation of
recombinant MCMV constructed for this study. Numbers correspond to nucleotide locations in the genome of MCMV strain Smith (accession
#GU305914). Left panel: MCMV-M35stop. ATG represents the start codon of M35 and STOP denotes the introduced stop cassette. Right panel:
MCMV-M35-myc. Linker-myc-His represents an 18 amino acid linker fused to a 10 amino acid myc-tag and a 6x Histidine tag. (B) Nycodenz-purified
virus preparations of MCMV-WT (WT), MCMV-M35stop-REV (REV), MCMV-M35stop (M35stop) and MCMV-M35-myc (M35-myc) adjusted to 5 x 104
MCMV M35 is a novel antagonist of pattern recognition receptor signaling
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006382 May 25, 2017 12 / 35
Next we wanted to investigate to which cellular compartment M35 localizes during MCMV
infection at different time points p.i. We performed a cellular fractionation assay to separate
the nuclear from cytoplasmic compartments of MCMV-M35-myc infected cells. To control
for purity of the cellular fractions, fractions were probed with antibodies specific for tubulin
(cytosolic fraction) and fibrillarin (nuclear fraction). At 1 hour p.i., M35 could be detected in
the nuclear fraction (Fig 6D). This remained the case for the duration of the time course. Previ-
ous studies have reported that M35 is present at low levels in the virion [48], which likely
explains our difficulties in detecting its presence in infected cells by immunofluorescence.
Simultaneously, we assayed for p65 nuclear translocation, as a marker of the activation of NF-
κB, in response to MCMV infection. At 1 hour p. i., p65 was restricted to the cytoplasmic frac-
tion and only at 2 hours p. i. we could detect p65 in the nucleus in MCMV-M35-myc infected
cells (Fig 6D). This suggests that the kinetics of M35 trafficking to the nucleus is more rapid
than that of p65 nuclear translocation upon MCMV infection.
Collectively, these data indicate that tegument M35 is shuttled to the nucleus in a timely
manner in order to counteract the onset of innate responses to MCMV infection and is only
de novo expressed at late time points post infection.
Tegument M35 modulates type I IFN induction in MCMV-infected
macrophages
To verify that M35 modulates type I IFN induction in the context of MCMV infection, we
assessed IFNβ transcription in the presence or absence of M35 in macrophages. Upon infec-
tion of iBMDM with WT MCMV, IFNβ transcription was detectable (Fig 7A). Infection with
MCMV-M35stop led to an elevated induction of IFNβ transcription compared to WT
MCMV. Notably, infection with UV-inactivated WT MCMV exceeded the response of
MCMV-M35stop infection. Since UV treatment abrogates de novo expression of viral genes,
this elevated IFNβ response induced by UV-inactivated MCMV indicates that M35 is not the
sole antagonist of type I IFN induction in MCMV. The same trend was observed for transcrip-
tion of the ISG CXCL10 (Fig 7A). We also infected primary BMDM and analyzed the levels of
secreted type I IFN. We observed that secreted type I IFN levels mirrored that of transcription,
in that MCMV-M35stop induced elevated levels of type I IFN compared to WT MCMV and
MCMV-M35stop-REV (Fig 7B). In addition, we also observed elevated levels of IFNα in pDC
and cDC infected with M35-deficient MCMV compared to MCMV-M35stop-REV (S4 Fig).
Given that the modulatory effect of M35 on type I IFN induction is apparent within the
first few hours of infection, it is highly likely that tegument M35, which is delivered into the
host cell by the viral particle, acts in an immunomodulatory manner. To test this hypothesis,
we prepared an M35-complemented MCMV-M35stop virus stock (MCMV-M35stop-comp).
The purified virus stock was generated from M2-10B4 cells stably expressing M35 infected
infectious viral particles were lysed in SDS loading buffer and separated by SDS-PAGE. Mock denotes a Nycodenz-purified preparation of uninfected
cells. Immunoblotting was performed with antibodies specific for M35, MCMV glycoprotein B (gB) or myc. (C) NIH3T3 fibroblasts were left untreated
(left panel) or were treated with 5 μg/ml actinomycin D (right panel) 15 minutes prior to infection. MCMV-M35-myc or MCMV-WT was added at an MOI
of 0.5 to the cells and infection was enhanced by centrifugation. The time point after centrifugation was defined as 0. After a 30 min incubation at 37˚C
to allow virus entry, unbound virus was removed with a citric acid buffer wash. Cells were then further incubated and then lysed at the indicated time
points. For treatment with actinomycin D, cells were cultured in the presence of actinomycin D for the entire duration of the time course. Cell lysates
were subjected to immunoblotting with antibodies specific for myc (to detect M35) as well as the MCMV proteins immediate-early protein 1 (IE1), early
protein M45 or late protein gB. Tubulin levels were determined with a tubulin antibody. (D) NIH3T3 fibroblasts were either treated with media alone or
infected with MCMV-M35-myc as described in (C). Whole cell lysates (WCL) were harvested at indicated time points and separated into cytoplasmic
(C) and nuclear (N) fractions. Expression of myc-tagged M35 was detected by immunoblotting with an anti-myc antibody, the MCMV protein IE1 with an
IE1-specific antibody, and p65 detected by an anti-p65 antibody. Tubulin and fibrillarin were used as controls for the cytoplasmic and nuclear fraction,
respectively.
https://doi.org/10.1371/journal.ppat.1006382.g006
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Fig 7. Tegument M35 modulates type I IFN responses upon MCMV infection. (A) Immortalized BMDM were infected with
MCMV-WT (WT), MCMV-M35stop (M35stop) or UV-inactivated MCMV-WT (UV WT) at an MOI of 0.1 and infection was enhanced
by centrifugation. Control cells were mock infected. After a 30 min incubation at 37˚C followed by a citric acid buffer wash, cells
were harvested for RNA extraction at 4 or 6 hours p.i. for quantification of IFNβ (left panel) and CXCL10 (right panel) transcription
by quantitative RT-PCR, respectively. Values were normalized to the housekeeping gene Rpl8. Data is shown as mean ± SD and
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with MCMV-M35stop, thereby incorporating M35 into the tegument, but the virus is unable
to induce novel M35 protein synthesis upon infection. We confirmed successful complemen-
tation by immunoblotting with an M35-specific antibody on purified virus stocks (Fig 7C).
We then infected primary BMDM and observed that infection with MCMV-M35stop-comp
elicited type I IFN levels comparable to WT MCMV, whereas, as before, MCMV-M35stop
induced elevated levels (Fig 7D). Notably, the restoration of the immunomodulatory effect of
M35 following infection with MCMV-M35stop-comp is already apparent at 6 hours p. i.,
which according to the time course of M35 expression (Fig 6C) is well before the expression of
newly synthesized M35. Therefore, we conclude that tegument-derived M35, but not de novo
synthesized M35, modulates type I IFN induction (S5 Fig).
Requirement of M35 for MCMV replication in macrophages is abolished
in the absence of IFNAR
Next, we examined the role of M35 during in vitro MCMV replication by multistep growth
curve analysis. M35 was not required for MCMV replication in cells of stromal fibroblast (M2-
10B4), endothelial (SVEC4-10) or epithelial (TCMK-1) origin (Fig 8A). In contrast, deletion of
M35 led to a marked growth deficit in macrophages, from which no productive infectious
virus could be detected (Fig 8B). To test if the requirement of M35 for MCMV replication in
macrophages could be attributed to its negative effect on type I IFN signaling, we performed
growth curves in IFNAR KO iBMDM, in which the type I IFN feedback loop is effectively
absent. We hypothesized that if the growth defect of MCMV lacking M35 in macrophages was
due to its loss in ability to modulate type I IFN signaling, we would expect to see rescue of
MCMV-M35stop in IFNAR KO iBMDM. Indeed, the ability of MCMV-M35stop to replicate
in macrophages was fully restored in the absence of IFNAR-dependent signaling (Fig 8C), sug-
gesting that the negative immunomodulatory effect of M35 is ameliorated in these cells. Our
data suggest that modulation of type I IFN signaling in macrophages by M35 is crucial for the
ability of MCMV to replicate in macrophages.
M35 modulates type I IFN induction in vivo
To assess if M35 modulates type I IFN induction during MCMV infection in vivo, we infected
transgenic mice expressing firefly luciferase under control of the natural IFNβ promoter
(IFNβ-luc reporter mice) [73] with MCMV-M35stop-REV or MCMV-M35stop. We then
examined the induction of IFNβ after MCMV infection by in vivo imaging. We observed lucif-
erase activity in the spleen and liver at 4 and 8 hours p.i. with MCMV-M35stop-REV. Notably,
compared to MCMV containing M35, luciferase activity was enhanced upon infection with
MCMV-M35stop already at 4 hours and even more strongly at 8 hours p.i. (Fig 9A).
To confirm that higher levels of type I IFN were produced in response to MCMV- M35stop
infection, we assayed IFNα and IFNβ levels in the serum of infected mice at 6 hours p.i. We
combined from three independent experiments. (B) Primary BMDM were infected with MCMV-M35stop-REV (REV) or
MCMV-M35stop (M35stop) at an MOI of 0.1 or were mock infected. Supernatants were harvested 16 hours p.i. for quantification of
IFNα (left panel) and IFNβ (right panel) levels by ELISA. Data is shown as mean ± SD and representative of three independent
experiments. (C) Nycodenz-purified virus preparations of MCMV-WT (WT), MCMV-M35stop (M35stop) and M35-complemented
MCMV-M35stop (M35stop-comp) adjusted to 5 x 104 infectious viral particles were lysed in SDS-loading buffer and separated by
SDS-PAGE. Mock denotes a Nycodenz-purified preparation of uninfected cells. Immunoblotting was carried out with antibodies
specific for M35 and MCMV glycoprotein B (gB). (D) Primary BMDM were infected at an MOI of 0.5 by addition of MCMV-M35stop-
REV (REV), MCMV-M35stop (M35stop) or M35-complemented MCMV-M35stop (M35stop-comp) to the culture medium.
Supernatants were harvested at indicated timepoints p.i. for quantification of IFNβ (top panel) and IFNα (bottom panel) levels by
ELISA. Data is combined from three independent experiments performed in duplicates and shown as mean ± SD. *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001.
https://doi.org/10.1371/journal.ppat.1006382.g007
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observed significantly elevated circulating type I IFN upon infection with MCMV-M35stop
(Fig 9B). A similar trend was observed in the spleen (Fig 9C). These results confirm that M35
is required for early modulation of the type I IFN response upon MCMV infection of the host.
MCMV lacking M35 has a severe growth defect in vivo
Next, we examined if modulation of type I IFN induction by M35 influences MCMV gene
expression and virus replication in vivo. BALB/c mice were infected with MCMV-M35stop-
REV or MCMV-M35stop and transcript levels for viral genes of all three temporal classes
(immediate early, early and late) in the liver and spleen were analyzed 24 hours p.i. The results
show that both viruses established productive infection in the tested organs, but the level of
viral transcripts after MCMV-M35stop infection were significantly lower compared to
MCMV-M35stop-REV infection (Fig 10). Reduced viral gene expression early after infection
might result in a reduced organ manifestation at later times points. This is visible in liver sec-
tions of BALB/c mice 72 hours p.i. (Fig 11), where only very few infectious foci were visible
Fig 8. M35 is a determinant for MCMV replication in macrophages. (A) Multistep growth analysis of MCMV-M35stop-REV (REV) or
MCMV-M35stop (M35stop) infection (MOI 0.05) in M2-10B4 stromal cells (left panel), SVEC-10 endothelial cells (central panel) or
TCMK-1 epithelial cells (right panel). Supernatant was harvested at indicated days post infection (dpi) and viral titers were determined by
standard plaque assay. The limit of detection is 10 PFU/ml. One representative of two independent experiments performed in triplicates
is shown. Data is shown as mean ± SD. (B) Multistep growth analysis of MCMV-M35stop-REV (REV) or MCMV-M35stop (M35stop)
infection (MOI 0.05) in immortalized WT BMDM as in (A). The limit of detection is 100 PFU/ml. One representative of two independent
experiments performed in triplicates is shown. Data is shown as mean ± SD. (C) Same as for (B) but with immortalized BMDM derived
from IFNAR1-/- mice.
https://doi.org/10.1371/journal.ppat.1006382.g008
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after MCMV-M35stop infection (Fig 11A, left panels). In contrast, a higher number of foci
were detected after infection with MCMV-M35stop-REV (Fig 11A, right panels). Using
2-color immunohistochemistry (2C-IHC), we simultaneously labeled the viral IE1 protein and
CD3ε molecules, which are expressed by T and NKT cells. Upon infection with MCMV-
M35stop we observed enhanced infiltration of CD3+ cells to the infected IE1+ liver cells
(Fig 11A), thereby forming protective nodular inflammatory foci (NIF) [74–78]. After
MCMV-M35stop infection, these NIF are composed of a lower number of IE1+ cells sur-
rounded by a higher number of CD3+ cells (Fig 11B) when compared to MCMV-M35stop-
Fig 9. M35 inhibits the induction of type I IFN in vivo. (A) In vivo whole-body imaging of luciferase activity in IFN-β+/Δβ-luc BALB/c reporter mice upon
i.v. infection with 2 x 105 PFU MCMV-M35stop-REV (REV) or MCMV-M35stop (M35stop) (left panel). Imaging was performed at 0, 4 and 8 hours p.i. after
i.v. injection of the luciferase substrate luciferin. Right panel shows corresponding quantification of luciferase activity by region of interest analysis of the
liver. Data is shown as mean ± SD and representative of two independent experiments. Type I IFN levels in serum (B) and spleen (C) following i.v.
infection with 4 x 105 PFU MCMV-M35stop-REV (REV) or MCMV-M35stop (M35stop) of BALB/c mice at 6 hours p.i. The levels of IFNα (respective left
panel) and IFNβ (respective right panel) in the serum and spleen organ homogenates were quantified by ELISA. Mock denotes uninfected mice. Data
shown is combined from two independent experiments. ***p<0.001 and ****p<0.0001.
https://doi.org/10.1371/journal.ppat.1006382.g009
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REV. These data suggest improved immune control following infection with MCMV-
M35stop.
In parallel, viral titers in the spleen were assessed to measure viral replication during the
peak phase of infection. Immunocompetent mice infected with MCMV-M35stop showed sig-
nificantly reduced viral titers in the spleen 3 days p.i. compared to MCMV-M35stop-REV
infected mice (Fig 12, left panel). A more pronounced effect was observed in the salivary
glands, where MCMV-M35stop was not detectable at 7, 14, and 28 days p.i. As expected,
MCMV-M35stop-REV was detectable in the salivary glands at all time points assessed, and
reached high titers at day 14 p.i. (Fig 12, right panel). In conclusion, the lack of M35 markedly
affects MCMV replication in the host at very early time points of infection, and is required for
the virus to reach the salivary glands, which is the essential organ for MCMV transmission.
In summary, our study identifies M35 as a novel modulator of the type I IFN response
downstream of PRR signaling and manifests its important role for viral replication in macro-
phages. The data also suggest that the ability of M35 to modulate the type I IFN response is
crucial for MCMV replication.
Discussion
Herpesviruses have evolved a plethora of strategies to avoid elimination by the host’s immune
system. To ensure the establishment of lifelong latency, herpesviruses have dedicated a large
portion of their genomes to genes involved in immune modulation, which target different, and
in some cases, multiple, arms of the immune system. This is well exemplified by the herpes
simplex virus type 1 ICP0 protein that efficiently targets intrinsic and innate immunity [79].
Upon cell entry, viruses are faced with a variety of challenges, among them the PRR-medi-
ated antiviral innate immune response. PRR directly bind PAMP and rapidly induce a signal-
ing cascade leading to the transcription of type I IFN and proinflammatory cytokines. Secreted
type I IFN then bind to the IFNAR, which activates a signaling cascade leading to the expres-
sion of ISG, creating an antiviral state.
In this study, we describe the identification of the poorly characterized MCMV protein,
M35, as a novel negative modulator of type I IFN transcription. Our unbiased luciferase-based
assay was designed on the hypothesis that MCMV must have evolved countermeasures against
the induction of PRR-mediated type I IFN signaling, which is initiated within minutes of viral
Fig 10. Infection with MCMV lacking M35 leads to lower levels of viral transcripts in vivo. BALB/c mice
were infected i.v. with 2 x 105 PFU MCMV-M35stop-REV (REV, black circle) or MCMV-M35-stop (M35stop,
open square). Expression of viral transcripts in liver and spleen was quantitated 24 hours p.i. by quantitative
RT-PCR specific for m123/IE1, m112/E1 and M86/MCP. Data were normalized to 107 cellular β-actin
transcripts. *p<0.05.
https://doi.org/10.1371/journal.ppat.1006382.g010
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infection. To modulate this rapid and potent antiviral response, we postulated that either a
viral protein present in the viral particle, or a viral protein with IE expression kinetics, would
be a prime candidate. Our screen of known or predicted tegument and IE proteins of MCMV
revealed the tegument protein M35 as a strong and novel inhibitor of IFNβ transcription. In
Fig 11. MCMV lacking M35 recruits antiviral CD3+ cells more efficiently to infected IE1+ tissue cells for the
formation of protective nodular inflammatory foci (NIF). (A) For the quantification of focal infiltrates in the
liver, tissue sections were collected randomly from four BALB/c mice per group on day 3 after i.v. infection with 2 x
105 PFU of either MCMV-M35stop (M35stop) or MCMV-M35stop-REV (REV). Sections were stained by 2-color
IHC (2C-IHC) for the expression of intranuclear viral IE1 protein (red staining) in infected liver tissue cells, as well
as for the CD3εmolecule (black staining) expressed by T cells and NKT cells. Sections were counterstained with
hematoxylin. Representative low-magnification overview images documenting a marked difference in the
numbers of NIF (upper panels). Higher resolution images of representative foci that are marked by arrows in the
overview images (lower panels). Scale bars represent 100 μm. (B) Data quantification and statistical evaluation of
differences for representative tissue section areas of 40 mm2. Each dot symbol (n = 29 for M35stop and n = 149
for REV) represents a focus of infection or a NIF in case of CD3+ cell recruitment. P values were calculated by
using the unpaired two-tailed Student’s t-test with Welch’s correction to account for unequal variances.
Differences between data sets are considered statistically significant for *p< 0.05 and***p<0.001.
https://doi.org/10.1371/journal.ppat.1006382.g011
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further assays, we could confirm that M35 alone, without the aid of additional MCMV pro-
teins, can efficiently inhibit type I IFN and proinflammatory cytokine responses downstream
of multiple PRR, namely cGAS-STING, RLR and TLR. Whilst the type I IFN response is driven
by both IRF- and NF-κB mediated transcription, we demonstrate that M35 targets type I IFN
transcription regulated by NF-κB alone.
Deletion of M35 from the MCMV genome and hence from the viral particle results in ele-
vated type I IFN responses in vitro and in vivo. Furthermore, we confirmed that, in the context
of viral infection, M35 is a component of the viral particle and could unequivocally show for
the first time that M35 is present within the infected cell for several hours after infection.
Indeed, upon MCMV infection, M35 is immediately shuttled to the nucleus and precedes the
translocation of p65 to the same compartment. In addition, by complementing M35-deficient
MCMV with M35, we demonstrated that tegument M35 and not de novo synthesized M35 is
responsible for downmodulation of type I IFN secretion. This is consistent with our initial
hypothesis that MCMV needs to counteract the rapid PRR-mediated immune response imme-
diately after infection.
The elevated type I IFN response in M35-deficient MCMV infected macrophages and mice
leads to a strong reduction of viral growth, highlighting the indispensable role played by M35
in the causal relationship between the type I IFN response and viral growth in vivo. In addition,
we observed that MCMV lacking M35 induces elevated IFNα secretion in pDC. Since TLR9 is
the major PRR in pDC, which induces a potent type I IFN response upon MCMV infection
[80], this observation suggests that M35 also modulates type I IFN transcription induced by
TLR9. In BMDM, which mainly produce proinflammatory cytokines upon TLR stimulation,
M35 inhibits the TLR response, resulting in reduced TNFα secretion. Since TNFα expression
is regulated by NF-κB and not by IRF, these results are in line with our luciferase assays show-
ing that M35 specifically inhibits NF-κB-, but not IRF-mediated transcription.
Fig 12. MCMV lacking M35 has a growth defect in the spleen and cannot establish chronic infection in
the salivary glands. MCMV load in the spleen (left panel) and salivary glands (right panel) following i.v.
infection of BALB/c mice with 2 x 105 PFU MCMV-M35stop-REV (REV) or MCMV-M35stop (M35stop).
Spleens were analyzed 3 days post infection (dpi) and salivary glands analyzed at indicated time points. Viral
titers were determined by standard plaque assay. Data shown is combined from two independent
experiments. Each symbol corresponds to an individual mouse; horizontal bars indicate mean values.
*p<0.05, **p<0.01.
https://doi.org/10.1371/journal.ppat.1006382.g012
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In a previous study, Tam and colleagues [81] have shown that a transposon insertional
mutation in the MCMV M35 ORF (Smith strain) results in defective viral growth in BALB/c
and severe combined immunodeficiency mice (which lack functional T and B cells), whereas
in vitro growth in NIH3T3 fibroblasts was comparable to WT MCMV. This is consistent with
our findings and underlines the importance of M35 for successful infection of its host. More-
over, we have extended upon this previous study to show that the modulation of type I IFN
responses by M35 is crucial for MCMV growth.
Two lines of evidence presented in this study illustrate the necessity for MCMV to downre-
gulate the type I IFN response in order to successfully establish an infection. First, in macro-
phages, which produce high levels of type I IFN, M35-deficient MCMV has a severe growth
defect, whereas no growth deficit was observed in non-immune cells. Second, in the absence of
the IFNAR, growth of M35-deficient MCMV was restored in macrophages. These results
strongly suggest that the higher levels of type I IFN induced by M35-deficient MCMV are the
cause for the severe growth defect observed in macrophages.
We have provided abundant evidence suggesting that M35 inhibits type I IFN transcription
within the nucleus: (i) M35 rapidly translocates to the nucleus upon infection, (ii) M35 neither
affects the phosphorylation and consequent activation of IRF3 or p65, nor the nuclear translo-
cation of IRF3 and p65, and (iii) M35 targets NF-κB-mediated IFNβ transcription. The mecha-
nism by which M35 translocates to the nucleus after viral entry merits further investigation,
but the fact that transiently expressed M35 localizes to the nucleus suggests that the viral capsid
is not necessary to direct M35 to the nuclear compartment. However, we cannot exclude the
possibility that, in the presence of the viral capsid and/or associated viral and/or cellular pro-
teins, the kinetics of M35 trafficking differ from those in cells which ectopically express M35.
The M35 sequence does not reveal homology to cellular proteins nor did analysis of its
sequence reveal any motifs found in, for example, known viral transcriptional activators. The
structure of the N-terminal domain of the HHV6B homologue of M35, U14, also does not give
insights into its possible function [82]. Further insights into the mechanism of how M35 mod-
ulates type I IFN transcription may be obtained by the analysis of successive N-and C-terminal
deletion mutants to narrow down the region important for the downmodulatory effect of M35
on type I IFN transcription. A comparative proteomics study with a nuclear M35 mutant
unable to downmodulate type I IFN responses and full length M35 may reveal cellular binding
partners that are either targeted or exploited by M35.
Within the human betaherpesvirus family, neither the HCMV homologue of M35, UL35,
nor the U14 protein of HHV6A, HHV6B, and HHV7, have been linked to the modulation of
the type I IFN response. It will be interesting to analyze if the type I IFN modulatory function
is conserved among these homologues of human betaherpesviruses, despite the low degree of
homology between M35 and HCMV UL35 (25.04% amino acid identity) as well as M35 and
HHV6B U14 (22.02% amino acid identity). Interestingly, the HCMV tegument protein UL35
has been described to influence the cell cycle and activate the DNA damage response [83].
There is emerging evidence to suggest that DNA damage triggers the type I IFN response
[84,85], which may indicate a link between the described role of UL35 in manipulating DNA
damage responses and a potential role in modulating innate immune signaling.
An impressive number of viral proteins that target PRR directly or their downstream signal-
ing pathways have been identified [86–89], and it is surprising that so far only a limited num-
ber of HCMV and MCMV proteins have been described that inhibit the PRR-mediated
proinflammatory or type I IFN response. M45 blocks NF-κB activation downstream of multi-
ple TLR as well as downstream of the interleukin 1 receptor [47]. It exerts this effect by induc-
ing degradation of NEMO, which is the regulatory subunit of the IKK complex that acts
upstream of NF-κB [47]. This function very likely explains our observation that M45 inhibits
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IFNβ transcription in our luciferase screen, thereby validating our screening assay. The
MCMV M27 protein targets signaling directly downstream of the IFNAR [39], whereas M35
does not directly affect this pathway, demonstrating its specificity for signaling events down-
stream of PRR.
Our observation that UV-inactivated MCMV induces much higher type I IFN responses
than M35-deficient MCMV highlights the existence of multiple MCMV-encoded modulators
of the type I IFN response. It will be interesting to generate MCMV mutants that lack multiple
evasion genes such as M45, M27 and M35 and different combinations thereof and compare
their potential to induce the type I IFN response and establish infection. It is feasible that
MCMV targets the type I IFN response at multiple steps as well as at multiple time points of
the viral life cycle.
In summary, our study identifies M35 as a novel type I IFN modulator. This is the first
described MCMV-encoded antagonist that interferes downstream of PRR signaling and which
is crucial for MCMV to establish infection in its host. Our finding provides a solid basis for
further studies on the detailed mechanism of how M35 may modulate transcription of type I
IFN. This study clearly emphasizes the utmost importance of timely countermeasures by
MCMV in its arms race with the host.
Materials and methods
Ethics statement
All animal experiments were performed in compliance with the German animal protection
law (TierSchG BGBI S. 1105; 25.05.1998). The mice were handled in accordance with good
animal practice as defined by FELASA and GV-SOLAS. All animal experiments were approved
by the responsible state office (Lower Saxony State Office of Consumer Protection and Food
Safety) under permit number #33.9-42502-04-12/0930 or by the ethics committee of the Land-
esuntersuchungsamt Rheinland-Pfalz, permit number 23177-07/G11-1-004.
Mice
Mice were bred at the animal facility of the Helmholtz Centre for Infection Research in Braun-
schweig and in the Central Laboratory Animal Facilities at the University Medical Center
Mainz and maintained under specific-pathogen-free conditions. STING knockout mice
(MPYS-/-/Tmem173tm1Camb) have been described [90]. BALB/c mice were purchased from
Janvier.
Viruses
Manipulation of the MCMV genome was carried out by en passant mutagenesis [91] on the
MCK-2 repaired MCMV BAC-plasmid [92]. Unless stated otherwise, MCMV-specific
sequences are underlined and pEP-KanS [91] served as the template for PCR. For construction
of the recombinant MCMV-M35stop, a linear PCR product was generated using primers
M35stopEPfor: 5’- GCTAGAGGCCCTCCTGGCGGTCCGCGTCAAACACAGGCTGGGCT
AGTTAACTAGCCACGAAGGTCAGACAGACACTAGGATGACGACGATAAGTAGGG-
3’ and M35stopEPrev: 5’- TGTAACAGATGACGGGCTCGAGTGTCTGTCTGACCTTCGT
GGCTAGTTAACTAGCCCAGCCTGTGTTTGACGCGGACAACCAATTAACCAATTCT
GATTAG-3’ to introduce a stop cassette (bold) at nucleotide position 46,134 (accession
#GU305914).
To restore full-length M35, a linear PCR product was generated using primers M35stopRe-
veEPfor: 5’- GCTAGAGGCCCTCCTGGCGGTCCGCGTCAAACACAGGCTGACGAAGGT
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CAGACAGACACTAGGATGACGACGATAAGTAGGG-3’ and M35stopReveEPrev: 5’-
TGTAACAGATGACGGGCTCGAGTGTCTGTCTGACCTTCGTCAGCCTGTGTTTGACG
CGGACAACCAATTAACCAATTCTGATTAG-3’ and the revertant virus was designated
MCMV-M35stop-REV.
For generation of C-terminally myc-His-tagged M35 virus, designated MCMV-M35-myc,
the EP-Kan-S cassette flanked by XbaI sites (bold) was amplified using primers XbaImycHi-
sEPfor: 5’- GCAGAATCTAGAGGGCCCTTCGAACAAAAACTCATCTCAGAAGAGGAT
CTGAATATGCATACAGGATGACGACGATAAGTAGGG-3’ and XbaImycHisEPfor 5’-
ATGCATTCTAGACAACCAATTAACCAATTCTGATTAG-3’ and inserted into the XbaI
site of pcDNA4/myc-His (Thermo Fisher) to generate pcDNA4/myc-His/EP-KanS. Here,
template specific sequences are underlined. Subsequently, a linear PCR product was generated
using the aforementioned pcDNA4/myc-His/EP-KanS construct as the template with primers
M35mycHisEPfor: 5’- GACCGTACTCCACAGTCCAGCGCGGCCGCCGTCGGCACGAGA
GCGAAGTGGAATTCTGCAGATATCCAGCA-3’ and M35mycHisEPrev: 5’-AAAGATATT
TTTTATTTCTCTCTCTCTTTTATTACTATTTCTTTCCCTCAATGGTGATGGTGATGAT
GACC-3’ and inserted at nucleotide position 47,469 (accession #GU305914). Recombinant
MCMV BACs were reconstituted after transfection of purified BAC DNA into M2-10B4 cells.
To get high titer virus stocks a single clone of each recombinant was expanded on M2-10B4
cells and purified on a 10% Nycodenz cushion. The resulting virus pellets were resuspended in
virus standard buffer (50 mM Tris-HCl [pH 7.8], 12 mM KCl, 5 mM EDTA) and stored at
-70˚C. To complement MCMV-M35stop with untagged M35, the MCMV-M35stop virus was
expanded on M2-10B4 cells stably expressing untagged M35 and was designated
MCMV-M35stop-comp. MCMV-GFP has previously been described [33].
Plasmids
pRL-TK, expressing Renilla luciferase under control of the thymidine kinase promoter, is com-
mercially available from Promega. pNF-κB Luc, containing five NF-κB responsive elements
(TGGGGACTTTCCGC) upstream of the firefly luciferase gene, is commercially available
from Agilent Technologies. pGL3basic-IFNβ-Luc (IFNβ-Luc) consists of the 812 bp murine
IFNβ promoter region [93] cloned into pGL3basic (Promega) upstream of the firefly luciferase
gene. The firefly luciferase reporter plasmids p125, consisting of the human IFNβ promoter
region (-125 to +19), its related mutant p125AA Luc (CC to AA, -58) with disrupted NF-κB
binding, and p55-CIB, containing 8 tandem repeat motifs (AAGTGA) corresponding to 7
repeats of an IRF binding element (AANNGAAA), were kindly provided by Takashi Fujita
(Kyoto University, Japan) [70,71]. pGL3basic-ISG56-Luc (ISG56-Luc) was constructed by
replacing the IFNβ promoter of pGL3basic-IFNβ-Luc with the 274 bp human ISG56
promoter.
IRF3-5D/CMVBL expresses a constitutively active form of human IRF-3 (S396D, S398D,
S402D, S404D, S405D) and was kindly provided by John Hiscott (Istituto Pasteur-Fondazione
Cenci Bolognetti, Italy). pEFBOS-murine cGAS, expressing untagged cGAS, and pEFBOS-
mCherry-murine STING were a kind gift from Andrea Ablasser (Global Health Institute,
Ecole Polytechnique Fe´de´rale de Lausanne, Switzerland). pIRES2-GFP, pMSCV, and pQCXIH
vectors were purchased from Clontech.
pWPIpuro-eGFP-IRF3, expressing an eGFP-human IRF3 fusion protein, was kindly pro-
vided by Marco Binder (University of Heidelberg, Germany) [94]. pcDNA4/LacZ-myc/His
was purchased from Invitrogen. LacZ-myc/His was subcloned into pMSCVhygro via the
BamHI/BglII sites to generate pMSCVhygro-LacZ-myc/His. pcDNA4-M35-myc/His expresses
the full-length protein M35 (nucleotides 45,912–47,471 of accession #GU305914) fused to a
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C-terminal myc/6xHis tag. The fused sequence of M35-myc/His was subcloned into
pMSCVhygro via the BglII/HpaI sites to generate pMSCVhygro-M35-myc/His. The fused
sequences of LacZ-myc/His and M35-myc/His were cloned into pQCXIH using PacI/HindIII
sites to generate pQCXIH-LacZ-myc/His and pQCXIH-M35-myc/His. Full length untagged
M35 was subcloned into pMSCVpuro via the BglII/EcoRI sites to generate pMSCVpuro-M35.
pcDNA3.1 M35-V5/His, pcDNA3.1 LacZ-V5/His and pcDNA3.1 M27-V5/His have been
described previously [95]. The MCMV ORF library was kindly provided by Ju¨rgen Haas (Uni-
versity of Edinburgh, Scotland) [51]. The library consists of untagged MCMV ORFs cloned
into the Gateway cloning system pDONR207 entry vector (Invitrogen). For expression in
mammalian cells, selected ORFs were transferred into the mammalian destination vector
pDEST40 using the LR clonase enzyme mix.
pcDNA4-ORF36-myc/His coding for ORF36 of KSHV was previously described [96,97].
pPolI Cal NS, containing the entire vRNA sequence for the NS segment of the pandemic
H1N1 influenza strain A/California/04/2009, was kindly provided by Toru Takimoto (Univer-
sity of Rochester Medical Center, Rochester, NY, USA) [98]. A splice acceptor site mutation
was introduced in the Cal NS sequence as previously described for the 1918 NS segment [99]
and Cal NS1 was then subcloned into pcDNA3.1(-) using specific primers.
All constructs were verified by sequencing. Primer sequences as well as sequences of all con-
structs are available upon request.
Cell lines
M2-10B4 (ATCC CRL-1972), SVEC4-10 (ATCC CRL-2181), TCMK-1 (ATCC CCL-139) and
human embryonic kidney 293-T/17 (293T, ATCC CRL-11268) cells were maintained in Dul-
becco’s modified Eagle’s medium (DMEM; high glucose) supplemented with 10% fetal calf
serum (FCS), 2 mM Glutamine (Gln) and 1% Penicillin/Streptomycin (P/S). The wild-type
immortalized murine bone marrow-derived macrophage (iBMDM) cell line was obtained
through BEI Resources, NIAID NIH (NR-9456) and cultured in the same medium as
described above supplemented with 50 μM β-mercaptoethanol. The IFNAR1-/- iBMDM were
immortalized by Dominic De Nardo (Walter and Eliza Hall Institute of Medical Research,
Parkville, VIC, Australia) from bone marrow provided by Paul J. Herzog (Hudson Institute of
Medical Research, Clayton, VIC, Australia) [100]. iBMDM stably expressing LacZ-myc and
M35-myc were generated by retroviral transduction using the constructs pMSCVhygro-LacZ-
myc/His and pMSCVhygro-M35-myc/His and selected with 150 μg/ml hygromycin.
NIH3T3 fibroblasts (DSMZ #ACC 59) were cultured in DMEM (high glucose) supple-
mented with 10% FCS, 2 mM Gln, 1% P/S, 1% non-essential amino acids and 1 mM sodium
pyruvate. NIH3T3 fibroblasts stably expressing LacZ-myc and M35-myc were generated by
retroviral transduction using the constructs pQCXIH-LacZ-myc/His and pQCXIH-M35-myc/
His and were selected with 300 μg/ml hygromycin. Control NIH3T3 cells were generated
using the corresponding pQCXIH empty vector. Stable introduction of eGFP-IRF3 into
NIH3T3 stably expressing LacZ-myc/His or M35-myc/His was performed by lentiviral trans-
duction using pWPIpuro-eGFP-IRF3 and additional selection with 10 μg/ml puromycin.
M2-10B4 cells stably expressing full-length untagged M35 were generated via retroviral trans-
duction using the construct pMSCVpuro-M35 and selected with 10 μg/ml puromycin.
Primary cells
For generation of primary plasmacytoid (pDC) and conventional dendritic cells (cDC), bone
marrow was isolated from wild type C57BL/6J mice. After erythrocyte lysis, cells were cultured
in RPMI 1640 medium supplemented with 10% FCS, 2 mM Gln, 1% P/S, and either 2.5% of
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medium from B16 cells expressing FMS-like tyrosine kinase 3 ligand (Flt3L) for pDC [101] or
20 ng/ml granulocyte macrophage colony-stimulating factor (GM-CSF, Peprotech) for cDC.
On day 8, non-adherent pDC were sorted from Flt3L cultures using the pDC isolation kit II
(Miltenyi Biotec) according to the manufacturer’s instructions, and non-adherent cDC were
collected from GM-CSF cultures. Primary BMDM were maintained in DMEM (high glucose)
supplemented with 10% FCS, 2 mM Gln, 1% P/S, 50 μM β-mercaptoethanol, and 5% macro-
phage colony stimulating factor (MCSF) and were prepared as described [96].
Antibodies and reagents
Murine anti-myc-tag (#2276, clone 9B11), rabbit anti-phospho-IRF3 (#4947, clone 4D4G, Ser-
ine 396), rabbit anti-fibrillarin (#2639, clone C13C3), rabbit anti-p65 (#4764S, clone C22B4)
and rabbit anti-phospho-NF-κB p65 (#3033, clone 93HI, Serine536) antibodies were pur-
chased from Cell Signaling Technology. Rabbit anti-IRF3 (#sc-9082) was from Santa Cruz
Technology. Mouse anti-tubulin (#T6199) and rabbit anti-calnexin (#C4731) were purchased
from Sigma-Aldrich. Mouse monoclonal antibodies against MCMV IE1 (m123/1E1 CapRi
#HR-MCMV-08), M55/gB (M55.01; HR-MCMV-05) and M45 (M45.01, CapRi #HR-MCMV-
13) were generated at the Center for Proteomics (CapRi), Faculty of Medicine, University of
Rijeka.
For production of mouse monoclonal antibodies directed against M35, nucleotides 4–579
(equivalent to aa 2–193) of the M35 ORF were subcloned into pET-28c (Novagen). Recombi-
nant protein was expressed in the E. coli BL21 (DE3) bacterial strain via IPTG induction.
Immunization of mice and generation of hybridoma cultures was performed as reported
previously [102]. Specificity of antibodies was validated by ELISA on protein used for immuni-
zation versus irrelevant His-tagged protein, as well as on lysates of MCMV WT infected cells
by immunoblotting. Antibodies were further tested on M35-myc expressing cell lysates by
immunoblotting, immunoprecipitation and immunofluorescence. Selected antibodies were
purified from hybridoma supernatants using protein G affinity chromatography.
2’3’-cGAMP and high molecular weight poly(I:C) were purchased from Invivogen. CpG-B
1826 and lipopolysaccharide (LPS) were purchased from MWG and Sigma-Aldrich, respec-
tively. Lipofectamine 2000 was from Thermo Fisher Scientific and Fugene HD was purchased
from Promega.
Luciferase-based reporter assays
cGAS/STING: 293T cells (25,000/well, 96-well plate) were transiently transfected with 10 μl of
Fugene HD/DNA complexes composed of 120 ng ORF expression plasmid or empty vector,
60 ng of pEFBOS-cGAS (stimulated) or pIRES2-GFP (unstimulated), 60 ng pEFBOS-
mCherry-STING, 100 ng pGL3basic-IFNβ-Luc, 10 ng pRL-TK and 1.2 μl of Fugene HD (Pro-
mega) diluted in Opti-MEM (Thermo Fisher Scientific). To analyze activation of other lucifer-
ase reporters, pGL3basic-IFNβ-Luc was substituted with 50 ng p125, 50 ng p125AA, or 1 ng of
p55-CIB reporter plasmids. For assaying NF-κB activity, the transfection was performed as
described, except 10 ng of the pNF-κB reporter plasmid and 20 ng pRL-TK were used.
pcDNA3.1(+) was added as stuffer plasmid. 20 hours post transfection cells were lysed in 1x
passive lysis buffer (PLB) (Promega).
IRF3-5D: 293T cells (25,000/well, 96-well plate) were transiently transfected with 10 μl of
Fugene HD/DNA complexes composed of 120 ng pcDNA3.1(+), 60 ng of IRF3-5D (stimu-
lated) or pIRES2-GFP (unstimulated), reporter plasmid (100 ng pGL3basic-IFNβ-Luc, 50 ng
p125, 50 ng p125AA, 1 ng p55-CIB, or 10 ng pNF-κB), 10 ng pRL-TK and 1 μl of Fugene HD
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(Promega) diluted in Opti-MEM (Thermo Fisher Scientific). pcDNA3.1(+) was added as
stuffer plasmid. Cells were lysed in 1x PLB at 20 hours post transfection.
IFN/ISG56: 293T cells (25,000/well, 96-well plates) were transiently transfected with 10 μl
of Fugene HD/DNA complexes composed of 120 ng ORF expression plasmid or empty vector,
100 ng pGL3basic-ISG56-Luc, 10 ng pRL-TK and 0.8 μl of Fugene HD diluted in Opti-MEM.
24 hours post transfection, cells were stimulated with 0.1 ng/ml recombinant human IFNβ
(PeproTech, #300-02BC) or mock stimulated and lysed 16 hours later in 1x PLB.
RIG-I: NIH3T3 fibroblasts (50,000/well, 24-well plates) were co-transfected with 40 μl of a
DNA-Fugene HD mixture consisting of 540 ng of empty vector or expression construct, 190
ng pGL3basic-IFNβ-Luc, 20 ng pRL-TK, and 2.6 μl of Fugene HD diluted in Opti-MEM. 24
hours post transfection, cells were washed with PBS and stimulated by addition of Newcastle
disease virus (NDV) in Opti-MEM or treated with Opti-MEM alone. 21 hours p.i., cells were
lysed in 1x PLB. For poly(I:C) stimulation, NIH3T3 cells were transfected as described above.
24 hours later, the medium was replaced with fresh medium and cells were mock-treated
(Lipofectamine only) or stimulated by transfection of 5 μg poly(I:C) complexed with 5 μl Lipo-
fectamine 2000 per well. Cells were lysed in 1x PLB 6 hours post stimulation.
Luciferase production was measured with the dual-luciferase reporter assay system and a
GloMax 96-microplate luminometer (both Promega). Luciferase fold induction was calculated
by dividing Renilla-normalized values from stimulated samples by corresponding values from
unstimulated samples.
In vivo infections and imaging
BALB/c mice were infected by the intravenous route with 4 x 105 PFU of the indicated recom-
binant MCMVs. Virus titers in spleen and salivary glands were determined by standard plaque
assay on M2-10B4 cells at indicated time points.
IFN-β+/Δβ-luc reporter mice on BALB/c background (Ifnb1tm1.2Lien) [73] were intravenously
infected with 2 x 105 PFU MCMV-M35stop or MCMV-M35stop-REV for whole body in vivo
imaging. Visualization of the reporter gene activity was achieved after intravenous injection of
150 mg/kg of D-luciferin in PBS (Calipers), followed by anesthesia using Isofluran (Baxter)
and monitored by the IVIS 200 imaging system (Calipers). Photon flux was quantified using
the Living Image 3.0 software. Light intensities are presented as pseudocolor overlays ranging
from red (most intense) to black (least intense).
Multistep growth curves
M2-10B4, SVEC4-10, TCMK-1 or iBMDM were infected in triplicate at an MOI of 0.05 for 1
hour at 37˚C. Cells were subsequently washed with citric acid buffer (pH 3.0) to remove
unbound virus and supplied with fresh culture medium. Ten percent of the supernatant was
harvested and replaced every 24 hours for six days and stored at -70˚C until titration on M2-
10B4 cells by standard plaque assay.
Quantitation of viral transcripts in vivo
Viral gene expression in liver and spleen was quantified by RT-qPCR specific for m123/IE1,
M112/E1 and M86/MCP, monitoring all kinetic stages of viral replication as described previ-
ously [103]. Total RNA was isolated from organ cells using the RNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions. Absolute quantification of viral transcripts was
performed using graded numbers of the specific in vitro transcripts as standard. For normali-
zation, cellular ß-actin transcripts were quantified in parallel.
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2-color immunohistochemistry analysis (2C-IHC)
2C-IHC for simultaneously detecting viral IE1 protein in the nuclei of infected cells (red stain-
ing) and membrane molecule CD3ε expressed by T cells and NKT cells (black staining) was
performed on liver tissue sections as described in greater detail previously [75,103,104]. In
brief, IE1 was labeled specifically with monoclonal antibody CROMA 101, and red staining
was achieved with alkaline phosphatase-conjugated polyclonal goat anti-mouse IgG (BioRad)
and the Fuchsin+ substrate-chromogen system (Dako). CD3ε was labeled specifically with a
rat monoclonal antibody, clone CD3-12 (BioRad), followed by black staining with biotin-con-
jugated polyclonal anti-rat Ig antibody (BD Biosciences) and the peroxidase-coupled avidin
biotin complex (Vectastain Elite ABC Kit), using DAB as the substrate and ammonium nickel
sulfate hexahydrate for color enhancement.
Fractionation
Separation of cytoplasmic and nuclear compartments was performed as previously described
[105] with minor modifications. Briefly, NIH3T3 fibroblasts were seeded at a density of 2.5 x
105 cells per well of a 6-well plate. The next day, cells were incubated with Opti-MEM contain-
ing MCMV at an MOI of 0.5. Infection enhancement was performed by centrifugation at 805
x g for 30 minutes at 4˚C. After centrifugation (defined as time point 0), cells were incubated
for 30 minutes at 37˚C and 7.5% CO2 to allow virus entry, then medium was removed and
cells were washed with citric acid buffer (pH 3.0) for 2 minutes at RT to remove extracellular
unbound virus. After replacement with normal media, cells were either collected immediately
(time point 0.5 h) or further incubated. Cells were collected in tubes containing 300 μl PBS
and centrifuged at 10,416 x g for 10 seconds at RT. Pellets were lysed with 300 μl ice-cold 0.1%
NP-40 in PBS. 45 μl of the lysate were removed and combined with 15 μl of 4x SDS loading
buffer (LB) and designated as the whole cell lysate (WCL). The remaining lysate was centri-
fuged at 16,873 x g for 10 seconds at RT and 45 μl of supernatant were added to 15 μl of 4x
SDS LB and designated as the cytosolic fraction (C). The pellet was washed with 300 μl of 0.1%
NP-40 in PBS followed by centrifugation at 16,873 x g for 10 seconds at RT. The pellet was
resuspended in 30 μl of 1x SDS LB and designated as the nuclear fraction (N). The WCL and
N fraction were sonicated twice for 5 seconds and boiled for 1 minute. For immunoblotting,
10 μl of the WCL and the C fraction and 5 μl of the N fraction were loaded per lane.
Immunoblotting
For analysis of IRF3 and p-IRF3 protein levels, 2 x 106 iBMDM stably expressing LacZ-myc or
M35-myc were stimulated with 3 μg/ml 2’3’-cGAMP. At the indicated time points, cells were
lysed in radioimmunoprecipitation (RIPA) buffer (20 mM Tris-HCl [pH 7.5], 1 mM EDTA,
100 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) with protease and
phosphatase inhibitors (Roche).
For analysis of p65 and phospho-p65 protein levels, 2.5 x 104 NIH3T3 fibroblasts stably
expressing M35-myc or its corresponding empty vector were stimulated by transfection of
10 μg/ml poly(I:C) complexed with Lipofectamine 2000. At the indicated time points, cells
were lysed as stated above.
For analysis of MCMV protein expression levels, MCMV was added to 1 x 105 NIH3T3
fibroblasts at an MOI of 0.5 and infection was enhanced by centrifugation at 805 x g at 4˚C for
30 minutes. After centrifugation (defined as time point 0), cells were incubated at 37˚C and
7.5% CO2 for 30 minutes followed by a citric acid buffer wash. At the indicated time points,
cells were lysed in RIPA lysis buffer including protease inhibitors. For analysis of M35 expres-
sion kinetics in the absence of transcription, a corresponding set of cells was cultured in the
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presence of 5 μg/ml actinomycin D 15 minutes prior to infection and for the duration of the
infection time course.
For analysis of virion-associated proteins, Nycodenz-purified virus stocks adjusted to 5 x
104 PFU were directly lysed in SDS LB and analyzed by SDS-PAGE and immunoblotting.
Cell lysates were cleared by centrifugation at 17,000 x g, separated by SDS-PAGE, trans-
ferred to nitrocellulose membranes, and probed with indicated antibodies. Secondary horse-
radish peroxidase (HRP) coupled antibodies were then added followed by development with
Lumi-Light (Roche Applied Science) or SuperSignal West Femto (Thermo Scientific) chemilu-
minescence substrates and membranes were exposed to film. Films were scanned and images
prepared using Adobe Photoshop CS5. Intensities of phospho-IRF3 bands were measured and
normalized to total IRF3 levels and phospho-p65 levels were normalized to tubulin levels using
ImageJ software analysis.
Stimulation of immortalized BMDM
Immortalized BMDM stably expressing M35-myc or LacZ-myc were stimulated with 2’3’-
cGAMP (3 or 10 μg/ml) to assess type I IFN induction. For assaying ISG induction, cells were
stimulated by the addition of IFNβ (100 U/ml, PBL Assay Science). For analysis of transcrip-
tion by RT-qPCR, total RNA was isolated at 2, 4, and 6 hours (for 2’3’-cGAMP) or at 1 and 2
hours (for IFNβ) post stimulation using the Qiagen RNeasy Plus Mini kit according to manu-
facturer’s instructions. To assess TNFα induction, immortalized BMDM stably expressing
M35-myc or its corresponding empty vector were stimulated with either 10 ng/ml LPS or
1 μM CpG-B 1826 for 16 hours.
ELISA
IFNα levels were detected using a rat anti-mouse IFNα capture antibody (PBL #22100–1) and
a rabbit anti-mouse IFNα detection antibody (PBL, 32100–1). IFNβ production was detected
using the PBL mouse IFNβ ELISA kit (PBL #42400–1) or the LumiKine mouse IFNβ ELISA kit
(Invivogen #lumi-mifnb) according to the manufacturer’s instructions. TNFα levels were
detected as described previously [96].
To determine type I IFN levels in the spleen of infected mice, spleens were homogenized in
20% w/v of PBS supplemented with protease inhibitors using the FastPrep-24 instrument (MP
Biomedicals). Triton X-100 was added to the homogenate to a final concentration of 0.01%
and samples were incubated on ice for 15 minutes. The homogenate was clarified via centrifu-
gation at 14,000 x g for 10 minutes at 4˚C and the supernatant analyzed by ELISA.
Quantitative RT-PCR
Immortalized BMDM were infected with MCMV at an MOI of 0.1 and infection was enhanced
by centrifugation for 30 minutes at 4˚C. After centrifugation, cells were incubated at 37˚C and
7.5% CO2 for 30 minutes, washed with citric acid buffer and further incubated. At 4 and 6
hours p.i., total RNA was extracted and purified using the RNeasy Mini Kit (Qiagen) followed
by DNase treatment. 100 ng of total RNA was used per reaction. Synthesis of cDNA and quan-
tification of gene transcripts were performed by quantitative PCR using the Superscript III
One-Step RT-PCR system (Invitrogen) on a LightCycler 96 instrument (Roche). Rlp8 served as
an internal control. PCR primers and Universal probe library (UPL, Roche) probes used were
as follows: Rlp8 (Rlp8for: caacagagccgttgttggt, Rlp8rev: cagcctttaagataggcttgtca, UPL probe 5);
IFNβ (IFNβfor: ctggcttccatcatgaacaa, IFNβrev: agagggctgtggtggagaa, UPL probe 18); CXCL10
(CXCL10for: gctgccgtcattttctgc, CXCL10rev: tctcactggcccgtcatc, UPL probe 3); IFIT3 (IFIT3-
for: tggactgagatttctgaactgc, IFIT3rev: agagattcccggttgacctc, UPL probe 3).
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Immunofluorescence
NIH3T3 fibroblasts stably expressing M35-myc/His, LacZ-myc/His, or corresponding empty
vector were seeded onto 24-well plates on acid-washed coverslips. The next day, NIH3T3
fibroblasts were permeabilized with ice-cold methanol for 5 minutes at -20˚C followed by fixa-
tion in 4% PFA in PBS for 15 minutes at RT. The coverslips were washed three times with PBS
and then incubated with primary antibody diluted in 1% BSA in PBS overnight. The coverslips
were washed three times with PBS and incubated with secondary antibody and Hoechst in 1%
BSA in PBS for 30 minutes at RT. Coverslips were mounted on glass microscope slides with
Prolong Gold (Invitrogen). Imaging was performed on a Nikon ECLIPSE Ti-E inverted micro-
scope equipped with a spinning disk device (Perkin Elmer Ultraview) and images were pro-
cessed using Volocity software (Improvision).
NIH3T3 fibroblasts stably expressing eGFP-IRF3 and M35-myc/His or eGFP-IRF3 and
LacZ-myc/His were seeded onto glass coverslips. 24 hours later, the medium was replaced
with fresh medium and cells were mock-treated or stimulated by transfection of 10 μg/ml poly
(I:C) (Invivogen) complexed with Lipofectamine 2000. At 3 and 6 hours post stimulation, cells
were fixed and visualized as described above. Quantification of IRF3 nuclear translocation was
based on at least 30 images and 100 cells per condition.
To analyze p65 translocation, NIH3T3 fibroblasts stably expressing M35-myc/His or its
corresponding empty vector were seeded onto glass coverslips and stimulated with poly(I:C)
as described above. At 2 and 4 hours post stimulation, cells were fixed and visualized as
described above. Quantification of p65 nuclear translocation was based on at least 20 images
and 300 cells per condition.
Statistical analysis
Differences between two data sets were evaluated by Student’s t-test (unpaired, two-tailed)
after log-transformation with Welch’s correction or log-transformed Mann Whitney U-test
using Graphpad Prism version 5.0 (GraphPad Software, San Diego, CA). P values<0.05 were
considered statistically significant.
Supporting information
S1 Fig. STING plays a crucial role for detection of MCMV in primary BMDM. Primary
BMDM generated from wildtype (WT) and STING knockout mice were infected with
MCMV-GFP at MOI 0.5 or 2 or left uninfected and IFNα/β levels at 16 hours p.i. were ana-
lyzed by ELISA. Data is shown as mean ± SD of three independent experiments.
(TIF)
S2 Fig. M35 does not affect IRF3 and p65 phosphorylation upon RLR stimulation. (A)
Quantification of phospho-IRF3 levels relative to total IRF3 levels was performed on Fig 4A
using ImageJ. (B) Quantification of phospho-p65 levels relative to total tubulin levels was per-
formed on three independent experiments using ImageJ. One representative immunoblot is
shown in Fig 4C.
(TIF)
S3 Fig. Activation of NF-κB and IRF responsive luciferase reporter constructs upon
expression of constitutively active IRF3. 293T cells were co-transfected with expression plas-
mids for either the constitutively active form of IRF3 designated IRF3-5D (stimulated) or GFP
(unstimulated) together with the pRL-TK luciferase plasmid, pcDNA and the IFNβ, p55-CIB,
pPRD-III/I, p125, p125AA or pNF-κB luciferase plasmids. At 20 hours post transfection, cells
were lysed and luciferase production was analyzed. Luciferase fold induction was calculated
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based on firefly luciferase values normalized to Renilla luciferase from stimulated samples
divided by corresponding values from unstimulated samples. Data set is combined from two
independent experiments and represented as mean ± SD.
(TIF)
S4 Fig. M35-deficient MCMV induces elevated IFNα secretion in dendritic cells compared
to WT MCMV. pDC and cDC were infected with MCMV-M35stop-REV (REV) or MCMV-
M35stop (M35stop) at an MOI of 0.01 (pDC), 0.1 (cDC), or left uninfected (mock). Superna-
tants were harvested 16 hours p.i. for quantification of IFNα levels by ELISA. Data is shown as
mean ± SD and representative of three independent experiments.
(TIF)
S5 Fig. M35 curtails type I IFN transcription downstream of multiple PRR. Sensing of
MCMV infection by multiple PRR, including cGAS, RIG-I-like receptors (RLR), and Toll-like
receptors (TLR), activates signaling cascades leading to the production of antiviral type I IFN.
Upon MCMV infection, tegument M35 is rapidly transported to the nucleus in order to specif-
ically interfere with NF-κB-mediated type I IFN transcription.
(TIF)
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